ES2095316T3 - Uso de antagonistas del factor activador de plaquetas como agentes antipruriticos. - Google Patents

Uso de antagonistas del factor activador de plaquetas como agentes antipruriticos.

Info

Publication number
ES2095316T3
ES2095316T3 ES91907987T ES91907987T ES2095316T3 ES 2095316 T3 ES2095316 T3 ES 2095316T3 ES 91907987 T ES91907987 T ES 91907987T ES 91907987 T ES91907987 T ES 91907987T ES 2095316 T3 ES2095316 T3 ES 2095316T3
Authority
ES
Spain
Prior art keywords
antagonists
paf
antipruritical
agents
platelet activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907987T
Other languages
English (en)
Inventor
David Frederick Woodward
Linda Sue Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24114767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2095316(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2095316T3 publication Critical patent/ES2095316T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

ESTE INVENTO MUESTRA UN METODO PARA TRATAR PRURITOS ADMINISTRANDO UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE ANTAGONISTAS DE PAF (FACTOR ACTIVANTE DE PLAQUETA) A UN MAMIFERO AFECTADO DE PRURITUS. LOS ANTAGONISTAS DE PAF PUEDEN, POR EJEMPLO, SELECCIONARSE DE ANALOGOS PAF SINTETICOS, PRODUCTOS NATURALES AISLADOS DE PLANTAS CON ACTIVIDAD ANTAGONISTA DE PAF, Y TRIAZOLOBENZODIAZEPINAS. LOS ANTAGONISTAS DE PAF SE APLICAN PREFERENTEMENTE A LA ZONA AFECTADA PERO TAMBIEN ES POSIBLE LA ADMINISTRACION SISTEMICA COMO ORAL, PARENTERAL, NASAL E INTRARECTAL.
ES91907987T 1990-05-31 1991-03-25 Uso de antagonistas del factor activador de plaquetas como agentes antipruriticos. Expired - Lifetime ES2095316T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53073990A 1990-05-31 1990-05-31

Publications (1)

Publication Number Publication Date
ES2095316T3 true ES2095316T3 (es) 1997-02-16

Family

ID=24114767

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907987T Expired - Lifetime ES2095316T3 (es) 1990-05-31 1991-03-25 Uso de antagonistas del factor activador de plaquetas como agentes antipruriticos.

Country Status (9)

Country Link
EP (1) EP0532512B1 (es)
JP (1) JP3142559B2 (es)
AT (1) ATE146079T1 (es)
AU (1) AU7690891A (es)
CA (1) CA2083611A1 (es)
DE (1) DE69123580T2 (es)
ES (1) ES2095316T3 (es)
IE (1) IE911848A1 (es)
WO (1) WO1991018608A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277846B1 (en) * 1990-05-31 2001-08-21 Allergan Sales, Inc. Use of platelet activating factor antagonists as anti-pruritic agents
WO1993017709A1 (en) * 1992-03-12 1993-09-16 Ono Pharmaceutical Co., Ltd. Antipruritic
JP3060287B2 (ja) * 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
US5854279A (en) * 1996-06-04 1998-12-29 Eisai Co., Ltd Therapeutic agent for dermatosis
FR2767692B1 (fr) * 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
CN110339191B (zh) * 2018-04-08 2022-08-02 成都百裕制药股份有限公司 银杏萜内酯在制备预防和/或治疗真性红细胞增多症的药物中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8418424D0 (en) * 1984-07-19 1984-08-22 Scras Inhibition of platelets aggregation
DE3502392A1 (de) * 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen

Also Published As

Publication number Publication date
DE69123580T2 (de) 1997-06-12
DE69123580D1 (de) 1997-01-23
EP0532512A1 (en) 1993-03-24
IE911848A1 (en) 1991-12-04
CA2083611A1 (en) 1991-12-01
AU7690891A (en) 1991-12-31
EP0532512B1 (en) 1996-12-11
WO1991018608A1 (en) 1991-12-12
ATE146079T1 (de) 1996-12-15
JPH05507467A (ja) 1993-10-28
JP3142559B2 (ja) 2001-03-07
EP0532512A4 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
ES2158452T3 (es) Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.
ITMI920528A1 (it) 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
DE69329073D1 (de) In liposomen verkapseltes taxol und verwendungsverfahren
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
GB1534823A (en) Dental chairs or like patient supporting devices
PT1135153E (pt) Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
EP0357030A3 (en) Use of thromboxane a2 receptor antagonists for the preparation of a pharmaceutical composition for treating skin injuries
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
EA199800052A1 (ru) Новые норпрегнаны для стимуляции гипоталамических эффектов
IT1205337B (it) Derivati amminometil-benzenici eteroaril-sostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni farmaceutiche che li contengono
DE3887151D1 (de) Inhibitoren für zellenzuwachs und methoden für krebsbehandlung.
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
ES2095316T3 (es) Uso de antagonistas del factor activador de plaquetas como agentes antipruriticos.
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
NO952828D0 (no) Synergiserende blanding med en antagonist-virkning på NK1- og NK2-reseptorer
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
MX9300250A (es) Metodo para emplear piridobenzodiazepinonas antimuscarinicas m1-selectivas en terapia de miopia axial.
ATE100465T1 (de) Analoge von bradykinin, dessen synthese und dessen benutzung in der therapie.
IT1260444B (it) Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
FI833101A (fi) Substituerade tert. -butanol-derivat, foerfarande foer deras framstaellning och dessa innehaollandeantimykotiska medel
ATE289506T1 (de) Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 532512

Country of ref document: ES